KEGG   DRUG: Lecanemab
Entry
D11678                      Drug                                   
Name
Lecanemab (USAN);
Lecanemab (genetical recombination) (JAN);
Leqembi (TN)
Product
Formula
C6544H10088N1744O2032S46
Exact mass
147088.6818
Mol weight
147179.66
Sequence
(Heqvy chain)
EVQLVESGGG LVQPGGSLRL SCSASGFTFS SFGMHWVRQA PGKGLEWVAY ISSGSSTIYY
GDTVKGRFTI SRDNAKNSLF LQMSSLRAED TAVYYCAREG GYYYGRSYYT MDYWGQGTTV
TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE
LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD
KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK
(Light chain)
DVVMTQSPLS LPVTPGAPAS ISCRSSQSIV HSNGNTYLEW YLQKPGQSPK LLIYKVSNRF
SGVPDRFSGS GSGTDFTLRI SRVEAEDVGI YYCFQGSHVP PTFGPGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H151-H207, H227-L219, H233-H'233, H236-H'236, H268-H328, H374-H432, H'22-H'96, H'151-H'207, H'227-H'219, H'268-H'328, H'374-H'432, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Class
Neuropsychiatric agent
 DG01968  Antidementia agent
Remark
Therapeutic category: 1190
ATC code: N06DX04
Product: D11678<JP/US>
Efficacy
Dementia therapeutic agent
  Disease
Alzheimer's disease [DS:H00056]
  Type
Monoclonal antibody
Comment
Treatment of Alzheimer's disease
Target
Amyloid beta [CPD:C16514 C16515]
  Network
nt06460  Alzheimer disease
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N06 PSYCHOANALEPTICS
   N06D ANTI-DEMENTIA DRUGS
    N06DX Other anti-dementia drugs
     N06DX04 Lecanemab
      D11678  Lecanemab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antidementia Agents
  Antidementia Agents, Other
   Lecanemab
    D11678  Lecanemab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   119  Miscellaneous
    1190  Miscellaneous
     D11678  Lecanemab (USAN); Lecanemab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG01968  Antidementia agent
   D11678  Lecanemab
Drug classes [BR:br08332]
 Neuropsychiatric agent
  DG01968  Antidementia agent
   D11678  Lecanemab
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11678
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11678
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11678
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D11678
Other DBs
CAS: 1260393-98-3
PubChem: 405226545
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system